Call Us : 0487-2381340
E-mail : info@integronpharma.com
 
 
 
   
Upgrade
Glimepiride is a medium-to-long acting sulfonylurea anti-diabetic drug.

It is sometimes classified as the first third-generation sulfonylurea,and sometimes classified as second-generation.

With glimepiride GI absorption is complete, with no interference of meals. Significant absorption of glimepiride was seen within 1 hour, and distributed throughout the body, bound to the plasma protein to an extent of 99.5% and it is metabolized by oxidative biotransformation and 60% is excreted in the urine, the remaining being excreted in the feces.

Like all sulfonylureas, glimepiride acts as an insulin secretagogue. It lowers blood sugar by stimulating the release of insulin by pancreatic beta cells and by inducing increased activity of intracellular insulin receptors

Metformin is an oral antidiabetic drug in the biguanide class. It is the first-line drug of choice for the treatment of type 2 diabetes, in particular, in overweight and obese people and those with normal kidney function. Its use in gestational diabetes has been limited by safety concerns. It is also used in the treatment of polycystic ovary syndrome, and has been investigated for other diseases where insulin resistance may be an important factor. Metformin works by suppressing glucose production by the liver.

Metformin is primarily used for type 2 diabetes however is increasingly being used in polycystic ovary syndrome (PCOS), non-alcoholic fatty liver disease (NAFLD) and premature puberty,three other diseases that feature insulin resistance; these indications are still considered experimental. The benefit of metformin in NAFLD has not been extensively studied and may be only temporary; although some randomized controlled trials have found significant improvement with its use, the evidence is still insufficient.
 

Home | About Us | Products | Manufacturers | Contact Us
Copyright © Integron Pharma Pvt Ltd. 2014 - 2015
Powered By : WEBAPPS Consulting